BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 10768250)

  • 1. [Antiviral therapy of hepatitis C].
    Erhardt A; Petry W; Ebel M; Jablonowski H; Heintges T; Häussinger D
    Z Gastroenterol; 2000 Mar; 38(3):259-69. PubMed ID: 10768250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future studies of combination therapy for chronic hepatitis C: optimizing response rates for each hepatitis C population.
    Main J
    J Hepatol; 1995; 23 Suppl 2():32-5; discussion 35-6. PubMed ID: 8720292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study.
    Bonny C; Fontaine H; Poynard T; Hézode C; Larrey D; Marcellin P; Bourlière M; Bronowicki JP; Merle P; Zarski JP; Sapey T; Guillemard C; Ughetto S; Henquell C; Nicolas C; Roche C; Randl K; Bommelaer G; Abergel A
    Aliment Pharmacol Ther; 2006 Aug; 24(4):593-600. PubMed ID: 16907892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience.
    Brillanti S; Miglioli M; Barbara L
    J Hepatol; 1995; 23 Suppl 2():13-5; discussion 15-6. PubMed ID: 8720288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What to do when standard therapy fails.
    Buti M; Esteban R
    Forum (Genova); 2000; 10(1):63-9. PubMed ID: 10717258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.
    Mousa DH; Abdalla AH; Al-Shoail G; Al-Sulaiman MH; Al-Hawas FA; Al-Khader AA
    Transplant Proc; 2004; 36(6):1831-4. PubMed ID: 15350490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hepatitis C virus genotype 4.
    Abdo AA; Lee SS
    J Gastroenterol Hepatol; 2004 Nov; 19(11):1233-9. PubMed ID: 15482528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of patients with hepatitis C and cirrhosis.
    Wright TL
    Hepatology; 2002 Nov; 36(5 Suppl 1):S185-94. PubMed ID: 12407593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis.
    Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    Intervirology; 2013; 56(1):37-45. PubMed ID: 23037768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon and ribavirin combination therapy: indications and schedules.
    Weiland O
    Forum (Genova); 2000; 10(1):22-8. PubMed ID: 10717255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C.
    Chemello L; Cavalletto L; Bernardinello E; Guido M; Pontisso P; Alberti A
    J Hepatol; 1995; 23 Suppl 2():8-12. PubMed ID: 8720287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hepatitis C: the recovery].
    Marcellin P
    Gastroenterol Clin Biol; 2009; 33(8-9):819-29. PubMed ID: 19541439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Side effects of interferon therapy for chronic hepatitis C].
    Arase Y
    Nihon Rinsho; 2006 Jul; 64(7):1363-7. PubMed ID: 16838657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interferon].
    Tamori A; Kawada N
    Nihon Rinsho; 2012 Apr; 70(4):620-4. PubMed ID: 22568143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New interferons in the treatment of chronic hepatitis C.
    Ruţă S; Cernescu C
    Roum Arch Microbiol Immunol; 2011; 70(2):85-92. PubMed ID: 22106515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.